Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 65.08M | 178.03M | 60.28M | 27.15M | 6.15M | 3.96M |
Gross Profit | 61.70M | 177.96M | 50.42M | -100.58M | -104.94M | -87.61M |
EBITDA | -149.75M | -52.66M | -128.20M | -155.59M | -155.68M | -125.81M |
Net Income | -169.76M | -70.81M | -113.87M | -165.46M | -158.09M | -130.09M |
Balance Sheet | ||||||
Total Assets | 130.63M | 245.96M | 282.62M | 328.92M | 469.55M | 451.14M |
Cash, Cash Equivalents and Short-Term Investments | 26.06M | 151.60M | 146.94M | 204.60M | 369.58M | 368.22M |
Total Debt | 48.68M | 74.21M | 25.23M | 23.08M | 25.47M | 23.71M |
Total Liabilities | 201.59M | 234.11M | 243.10M | 247.04M | 263.58M | 109.92M |
Stockholders Equity | -70.96M | 11.85M | 39.51M | 81.88M | 205.96M | 341.23M |
Cash Flow | ||||||
Free Cash Flow | -191.71M | -75.93M | -145.76M | -171.51M | 1.95M | -56.50M |
Operating Cash Flow | -190.03M | -73.21M | -140.88M | -141.77M | 10.73M | -53.59M |
Investing Cash Flow | 1.79M | -58.95M | 176.54M | 89.14M | 75.80M | -278.92M |
Financing Cash Flow | 1.34M | 78.75M | 880.00K | 12.87M | 3.29M | 340.05M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.95B | -0.40 | -41.67% | 2.21% | 22.29% | -1.85% | |
47 Neutral | $103.69M | ― | -63.24% | ― | -87.65% | 11.76% | |
41 Neutral | $13.52M | ― | -1341.37% | ― | -53.61% | -93.14% | |
39 Underperform | $27.50M | ― | 91.63% | ― | -44.63% | 26.80% | |
39 Underperform | $155.49M | ― | -76.34% | ― | ― | -41.69% | |
37 Underperform | $73.59M | ― | -37.25% | ― | ― | 62.83% | |
35 Underperform | $44.21M | ― | -146.87% | ― | ― | -17.96% |
Adaptimmune Therapeutics announced changes in its executive team due to redundancy, affecting Gavin Wood, the Chief Financial Officer, and John Lunger, the Chief Patient Supply Officer. Mr. Wood’s employment will end on September 9, 2025, with a severance package including a year’s salary and other benefits, while Mr. Lunger’s termination is effective August 31, 2025, with similar severance terms. These changes reflect the company’s ongoing restructuring efforts, impacting its operational dynamics and potentially influencing stakeholder relations.
On August 15, 2025, Adaptimmune announced a separation agreement with Cintia Piccina, whose role as Chief Commercial Officer was terminated due to redundancy on August 8, 2025. As part of the agreement, Piccina will receive a severance payment equivalent to 12 months of her 2025 base salary, amounting to $473,800, and will have until January 30, 2032, to exercise her vested share options.
Adaptimmune Therapeutics plc, a company involved in the biotechnology industry, faced compliance issues with Nasdaq’s listing rules due to its American Depositary Shares trading below the required minimum bid price. On November 1, 2024, the company was notified of non-compliance and given until April 30, 2025, to resolve the issue. Despite an extension granted on May 1, 2025, to October 27, 2025, the company’s shares continued to fall, prompting Nasdaq to issue a delisting notice on August 14, 2025. Adaptimmune intends to request a hearing to present its compliance plan and seek additional time to meet the listing requirements, with its shares remaining on the Nasdaq Capital Market under the symbol ‘ADAP’ during the process.
On August 7, 2025, Adaptimmune announced the termination of Dr. Elliot Norry as Chief Medical Officer, effective August 8, 2025, due to redundancy. Dr. Norry will receive a severance package including a year’s salary and healthcare coverage. Similarly, Dr. Joanna Brewer’s role as Chief Scientific Officer will end on August 31, 2025, with a similar severance arrangement. Gavin Wood’s termination as Chief Financial Officer, initially announced in December 2024, will also conclude on August 31, 2025, with a severance package including a year’s salary and a pro rata bonus. These changes reflect a strategic restructuring within the company.
On July 31, 2025, Adaptimmune Therapeutics completed a significant transaction involving the sale of its cell therapy assets to USWM CT, LLC, receiving $55 million and potential future milestone payments. This transaction also allowed Adaptimmune to settle its $29.1 million debt with Hercules Capital, thereby improving its financial position and potentially impacting its future operations and market strategy.
On July 27, 2025, Adaptimmune Therapeutics entered into an agreement to sell its cell therapy assets, including TECELRA, lete-cel, afami-cel, and uza-cel, to US WorldMeds for $55 million, with potential additional payments of up to $30 million based on milestone achievements. This transaction is part of a broader restructuring plan by Adaptimmune to maximize value from its remaining assets and involves significant workforce reductions. The restructuring will see key executives depart and is expected to incur pre-tax costs of approximately $7-8 million. The transaction aims to ensure the continued availability of TECELRA to patients and support the development of other therapies by US WorldMeds.
On July 16, 2025, Adaptimmune Therapeutics plc entered into a settlement agreement with The University of Texas M.D. Anderson Cancer Center to resolve litigation related to a Strategic Alliance Agreement from 2016. The settlement, which involves financial payment obligations, is not expected to have a material adverse effect on Adaptimmune’s financial position or operations.